From the Journals

Methotrexate in Preventing RA: Benefits in ACPA-Negative Patients, and Is It Cost Effective?


 

A 1-year course of methotrexate (MTX) in clinically suspected arthralgia may prevent the development of rheumatoid arthritis (RA) in at-risk individuals who test negative for anti-citrullinated protein antibody (ACPA), according to 4-year results from the TREAT EARLIER study.

While 2-year data did not show a preventive effect, researchers risk-stratified patients in this most recent data. The previous study also grouped all individuals together, while this new analysis separated patients by seropositivity.

“Heterogeneity in risk of rheumatoid arthritis development in ACPA–negative participants with clinically suspect arthralgia might have concealed a treatment effect due to dilution,” wrote senior author Annette H. van der Helm-van Mil, MD, PhD, professor of rheumatology at Leiden University Medical Center, Leiden, the Netherlands, and colleagues. “Therefore, risk-stratified analyses are required to adequately assess the possibility of prevention of rheumatoid arthritis in people with clinically suspect arthralgia who are ACPA–negative.”

Dr. Annette van der Helm-van Mil, professor of rheumatology at Leiden University Medical Center, Leiden, the Netherlands Leiden University

Dr. Annette van der Helm-van Mil

To qualify for the study, participants needed to have recent-onset joint pain that a treating rheumatologist suspected of progressing to RA. Second, participants had to have subclinical joint inflammation, detected via MRI.

These are “promising results” for a group where predicting risk for RA has been more difficult than for their ACPA–positive counterparts, said Kevin Deane, MD, PhD, a professor of medicine and rheumatologist at the University of Colorado School of Medicine, Aurora, who was not involved with the study. However, additional research is necessary to investigate these findings.

The clinical utility of this finding is also unclear, he noted, as it would be an “extensive process” for all ACPA–negative individuals with joint pain to undergo MRI screening, he continued.

“It’s hard to find people who would meet these criteria, and healthcare systems need to understand how ultimately this could be implemented in clinical care,” he said.

Adding Risk Stratification

The TREAT EARLIER trial included 236 participants; nearly two thirds were women, and 77% were ACPA–negative (specifically for anti-cyclic citrullinated peptide 2). Patients randomly assigned to active treatment received a single intramuscular glucocorticoid injection (methylprednisolone 120 mg) upon inclusion and then completed a 1-year course of MTX. The comparator group received a single placebo injection at the beginning of the trial and a 1-year course of placebo tablets. All trial screenings and visits were conducted at the Leiden University Medical Center.

At the 2-year mark, there was no difference in the development of RA between the treatment and placebo groups, although there was improvement in joint pain, physical functioning, and MRI-detected joint inflammation in all at-risk groups given MTX — ACPA–positive patients and those at high risk for clinical arthritis development.

MTX delayed the onset of RA, with a statistically significant difference between treatment and placebo at 6 and 12 months, but not at 24 months.

For this 4-year analysis, published in The Lancet Rheumatology, authors stratified patients at their time of enrollment according to their risk of developing RA based on a published model for predicting inflammatory arthritis. Predictors included ACPA positivity (2 points), rheumatoid factor positivity (1 point), more than two locations of subclinical inflammation on MRI (2 points), and presence of metacarpophalangeal extensor tenosynovitis on MRI (1 point).

Patients with at least 4 points were classified as “high-risk,” with a 70% or higher predicted risk of developing RA. Participants with 2-3 points were at “increased risk” — translating to a 25%-70% higher likelihood of developing the condition. Low-risk patients, with 0-1 points, had < 25% chance of developing RA.

Of the 182 ACPA–negative participants in the study, none were considered high risk, 66 (36%) were at increased risk, and 116 (64%) were at low risk.

Pages

Recommended Reading

After Remission Failure in Early RA, Adding Etanercept No Better Than Adding Leflunomide
MDedge Rheumatology
We Asked 7 Doctors: How Do You Get Patients to Exercise?
MDedge Rheumatology
Teclistamab Promising as a Treatment of Last Resort for Refractory Autoimmune Diseases
MDedge Rheumatology
Stroke Risk from Atrial Fibrillation Rises in Presence of Rheumatoid Arthritis
MDedge Rheumatology
Kidney Disease May Accelerate With Higher Rheumatoid Arthritis Disease Activity
MDedge Rheumatology
Diets Higher in Ultra-Processed Foods Raise Risk for Rheumatoid Arthritis
MDedge Rheumatology
Early Use of Steroids Linked to Prolonged Treatment in Early Rheumatoid Arthritis
MDedge Rheumatology
Rheumatology Clinic Interventions for Smoking, Blood Pressure ‘Make a Big Difference’
MDedge Rheumatology
Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential Risks
MDedge Rheumatology
ILD Subtypes in Rheumatoid Arthritis Carry Different Risk Factor Profiles
MDedge Rheumatology